Penumbra, Inc. vs Abbvie Inc.
PEN vs ABBV — side-by-side comparison from reported financials. PEN leads 5, ABBV leads 4 of 9 comparable metrics.
Penumbra, Inc.
PEN · Healthcare
$319.40+0.59%Strong
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | PEN | ABBV |
|---|---|---|
| Price | $319.40 | $276.43 |
| Market cap | $12.6B | $488B |
| Revenue (TTM) | $1.50B | $64.4B |
| Revenue growth | +18.3% | +1.8% |
| Net margin | 10.7% | 9.8% |
| Free cash flow | $216M | $18.2B |
| Net cash (debt) | — | ($56.2B) |
| 1-year price return | +22.2% | +19.8% |
| P/E | 78.3 | 77.4 |
| P/E vs own history (cheap-side %) | 76% | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | 11% | 96% |
| Altman Z-score | 18.49 | 2.33 |
| CV checks passed | 9 of 10 | 9 of 10 |
| Employees | 4,700 | 57,000 |
Full résumé-style profiles: PEN CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.